NCT03698071View on ClinicalTrials.gov

Soluble CD95 Ligand Role in the Pathophysiology of Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis

NACompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

December 14, 2018

Primary Completion Date

September 18, 2024

Study Completion Date

September 18, 2024

Conditions
ANCA Associated Vasculitis
Interventions
BIOLOGICAL

blood sample

30 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation

BIOLOGICAL

urine sample

6 ml

Trial Locations (1)

Unknown

CHU de Bordeaux - Service d'Immunologie et Immunogénétique, Bordeaux

All Listed Sponsors
collaborator

National Research Agency, France

OTHER

lead

University Hospital, Bordeaux

OTHER

NCT03698071 - Soluble CD95 Ligand Role in the Pathophysiology of Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis | Biotech Hunter | Biotech Hunter